NO20091613L - Fremgangsmate for generering av aktive antistoffer mot et resistansantigen, antistoffer fremskaffet ved nevnte fremgangsmate og deres anvendelser - Google Patents

Fremgangsmate for generering av aktive antistoffer mot et resistansantigen, antistoffer fremskaffet ved nevnte fremgangsmate og deres anvendelser

Info

Publication number
NO20091613L
NO20091613L NO20091613A NO20091613A NO20091613L NO 20091613 L NO20091613 L NO 20091613L NO 20091613 A NO20091613 A NO 20091613A NO 20091613 A NO20091613 A NO 20091613A NO 20091613 L NO20091613 L NO 20091613L
Authority
NO
Norway
Prior art keywords
antibodies
tumor
generating active
resistance
resistant
Prior art date
Application number
NO20091613A
Other languages
English (en)
Norwegian (no)
Inventor
Liliane Goetsch
Alexandra Jouhanneaud
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20091613L publication Critical patent/NO20091613L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20091613A 2006-09-28 2009-04-22 Fremgangsmate for generering av aktive antistoffer mot et resistansantigen, antistoffer fremskaffet ved nevnte fremgangsmate og deres anvendelser NO20091613L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
PCT/EP2007/060243 WO2008046724A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Publications (1)

Publication Number Publication Date
NO20091613L true NO20091613L (no) 2009-06-26

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091613A NO20091613L (no) 2006-09-28 2009-04-22 Fremgangsmate for generering av aktive antistoffer mot et resistansantigen, antistoffer fremskaffet ved nevnte fremgangsmate og deres anvendelser

Country Status (21)

Country Link
US (2) US8241646B2 (https=)
EP (4) EP2497491B1 (https=)
JP (1) JP5774276B2 (https=)
KR (1) KR101504770B1 (https=)
CN (1) CN101516394B (https=)
AR (1) AR063061A1 (https=)
AU (1) AU2007312437C1 (https=)
BR (1) BRPI0717246A2 (https=)
CA (1) CA2663561A1 (https=)
FR (1) FR2906533B1 (https=)
IL (1) IL197790A (https=)
MA (1) MA30954B1 (https=)
MX (1) MX2009003245A (https=)
NO (1) NO20091613L (https=)
NZ (1) NZ576420A (https=)
RU (1) RU2515904C2 (https=)
TN (1) TN2009000102A1 (https=)
TW (1) TWI516276B (https=)
UA (1) UA102812C2 (https=)
WO (1) WO2008046724A1 (https=)
ZA (1) ZA200902697B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
US20120282211A1 (en) * 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
TW201613615A (en) 2014-06-30 2016-04-16 Academia Sinica Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AR105553A1 (es) * 2015-04-27 2017-10-18 Pf Medicament Anticuerpo del receptor del factor 1 del crecimiento similar a insulina (igf-1r) y su utilización para diagnosticar cáncer
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一）
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
US10981991B2 (en) * 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6261596A (ja) * 1985-09-11 1987-03-18 Japan Found Cancer Res 薬剤耐性癌に関するモノクロ−ナル抗体およびその製造
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
KR950700061A (ko) * 1992-02-06 1995-01-16 스티븐 엘. 네스비트 테트라아릴에틸렌에 의한 다중 약물 내성의 역전(reversal of multi -drug resistance by tetraarylethylenes)
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
DE60312639T2 (de) 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
US20040121965A1 (en) 2002-09-20 2004-06-24 Wyeth Holdings Corporation Method of treating resistant tumors
WO2005035721A2 (en) * 2003-10-08 2005-04-21 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
WO2005077385A2 (en) 2004-02-18 2005-08-25 Gpc Biotech Ag Methods for treating resistant or refractory tumors
EP1742060A1 (en) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders.

Also Published As

Publication number Publication date
ZA200902697B (en) 2010-04-28
US8808667B2 (en) 2014-08-19
CN101516394B (zh) 2014-07-30
WO2008046724A1 (en) 2008-04-24
EP2491945B1 (en) 2016-12-07
CA2663561A1 (en) 2008-04-24
TN2009000102A1 (en) 2010-08-19
AR063061A1 (es) 2008-12-23
EP2497491B1 (en) 2017-03-01
US20100146650A1 (en) 2010-06-10
EP2491945A1 (en) 2012-08-29
UA102812C2 (ru) 2013-08-27
KR101504770B1 (ko) 2015-03-20
TW200822934A (en) 2008-06-01
MX2009003245A (es) 2009-07-07
NZ576420A (en) 2012-05-25
JP5774276B2 (ja) 2015-09-09
EP2494984B1 (en) 2017-01-04
FR2906533A1 (fr) 2008-04-04
AU2007312437B2 (en) 2014-01-23
RU2009114682A (ru) 2010-11-20
EP2497491A1 (en) 2012-09-12
MA30954B1 (fr) 2009-12-01
IL197790A (en) 2016-10-31
BRPI0717246A2 (pt) 2013-10-08
AU2007312437C1 (en) 2014-04-10
EP2491945B9 (en) 2017-03-08
HK1131063A1 (en) 2010-01-15
US20130028835A1 (en) 2013-01-31
KR20090057469A (ko) 2009-06-05
JP2010504743A (ja) 2010-02-18
EP2081592A1 (en) 2009-07-29
RU2515904C2 (ru) 2014-05-20
TWI516276B (zh) 2016-01-11
FR2906533B1 (fr) 2013-02-22
EP2081592B1 (en) 2016-01-13
EP2494984A1 (en) 2012-09-05
US8241646B2 (en) 2012-08-14
AU2007312437A1 (en) 2008-04-24
IL197790A0 (en) 2011-08-01
CN101516394A (zh) 2009-08-26

Similar Documents

Publication Publication Date Title
NO20091613L (no) Fremgangsmate for generering av aktive antistoffer mot et resistansantigen, antistoffer fremskaffet ved nevnte fremgangsmate og deres anvendelser
NO20076401L (no) Diarylhydantoinforbindelser
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
NO20084396L (no) Kombinasjonsterapi
NO20092360L (no) Nye antiproliferasjonsantistoffer
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
EP2336174B8 (en) Human monoclonal antibodies against Hendra and Nipah viruses
NO20084479L (no) Antitumor celleantigen antistoff terapi
CY1120168T1 (el) Rna συνθεση για θεραπεια μη-μικροκυτταρικων καρκινων πνευμονα (nsclc)
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
NO20056236L (no) Behandling med anti-VEGF-antistoffer
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
NO20080302L (no) Humane anti-B7RP1 noytraliserende antistoffer
NO20074446L (no) DR5-antistoffer og anvendelser derav
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
NO20050719L (no) Transplantat akseptinduserende celler av monocytisk opprinnelse og deres fremstilling og anvendelse
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
NO20070651L (no) Sammensetninger av statiner med bronkodilatorer
NO20083444L (no) IGF-IR-antagonister som adjuvanser ved behandling av prostatacancer
AR054758A1 (es) Proceso de elaboracion de un epoxido a partir de una clorhidrina
NO20091598L (no) P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav
WO2008067408A3 (en) Method of isolating and propagating stem cells from benign tumors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application